Analyst Ratings for Par Pharmaceutical (PRX)
PRX Rating Summary
PRX Price Target Summary
- Highest: $50.00 (ThinkEquity)
- Lowest: $34.00 (Goldman Sachs)
- Average: $41.80
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$41.80 (-16.4%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/8/2012 | UBS | Downgrade | Neutral (Buy) |
N/A (N/A) |
50.02 | 49.98 | -0.08% | Details |
| 7/20/2012 | ThinkEquity | Downgrade | Hold (Buy) |
50.00 (N/A) |
50.05 | 49.98 | -0.14% | Details |
| 7/16/2012 | Leerink Swann | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
36.58 | 49.98 | 36.63% | Details |
| 7/16/2012 | Needham & Company » Updated 8/24/2012 |
Downgrade | Hold (Strong Buy) |
N/A (N/A) |
36.58 | 49.98 | 36.63% | Details |
| 7/16/2012 | Piper Jaffray | Downgrade | Neutral (Overweight) |
50.00 (N/A) |
36.58 | 49.98 | 36.63% | Details |
| 7/16/2012 | Buckingham Research | Downgrade | Neutral (Buy) |
N/A (N/A) |
51.41 | 49.98 | -2.78% | Details |
| 3/16/2012 | JPMorgan | New Coverage | Neutral (N/A) |
40.00 (N/A) |
37.46 | 49.98 | 33.42% | Details |
| 12/9/2011 | Barclays » Updated 5/31/2012 |
New Coverage | Equalweight (N/A) |
35.00 (N/A) |
31.46 | 49.98 | 58.87% | Details |
| 3/25/2011 | BofA/Merrill Lynch | Upgrade | Buy (N/A) |
N/A (N/A) |
29.33 | 49.98 | 70.41% | Details |
| 8/5/2010 | Caris & Co. | Upgrade | Buy (N/A) |
N/A (N/A) |
27.53 | 49.98 | 81.55% | Details |
